A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy

This study is testing a new way to give a cancer immunotherapy drug called rilvegostomig — by injection under the skin (subcutaneous) rather than through an IV. It is studying how the drug moves through the body and whether this delivery method is safe for people with advanced solid tumors. **You may be eligible if...** - You have an advanced solid tumor (spread or cannot be surgically removed) that has been confirmed by biopsy - You have already received standard cancer treatment - You are in reasonably good physical health and able to carry out daily activities - You weigh at least 30 kg - Your life expectancy is at least 12 weeks - Your organs (kidneys, liver, blood counts) are functioning adequately **You may NOT be eligible if...** - You have had an organ transplant - You have had another primary cancer in the past 2 years - You have serious uncontrolled illnesses Talk to your doctor to see if this trial is right for you.